Nina Vladislavovna Malkevich | Senior Director and Filovirus Vaccines Lead
International AIDS Vaccine Initiative

Nina Malkevich, PhD is a Senior Director and Project Team Lead at the International AIDS Vaccine Initiative (IAVI) is leading Marburg and Sudan Filovirus vaccine development programs. Prior to joining IAVI, Nina worked as a Senior Nonclinical Subject Matter Expert at BARDA on multiple vaccine programs (SARS-CoV-2, Filoviruses and Zika) and animal model development. Nina has 18 years of experience in scientific leadership and pharmaceutical product development, to include all aspects of vaccine development from R&D to licensure. Nina advanced multiple vaccine candidates, to include botulinum, anthrax, tuberculosis and HIV from pre-clinical testing to clinical trials. Author of 25 scientific publications who successfully completed more than 50 animal studies in support of licensure of Medical Countermeasures under the FDA Animal Rule. Nina was responsible for the GLP animal studies in support of the BLA for BioThrax® (Anthrax Vaccine Adsorbed) under the FDA Animal Rule. Nina’s industry experience is to include employment at DynPort Vaccine Corporation, a GDIT company, where she led a late-stage program aimed to develop Recombinant Botulinum Vaccine. Nina’s nonclinical pharmaceutical experience was primarily acquired at Emergent BioSolutions, where she served as a Technical Lead on anthrax vaccines and therapeutics programs.